Disease Modifying Agent for Ankylosing Spondylitis Peripheral Symptoms

Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the spine, but it can also involve peripheral joints, tendons, and entheses.

Managing Peripheral Manifestations in AS

Disease-modifying antirheumatic drugs (DMARDs) are crucial for managing the inflammatory activity and preventing joint damage in AS. When focusing on the peripheral manifestations, specific DMARDs are considered based on efficacy and patient factors.

Evaluating Disease Modifying Agents for Peripheral AS

Let's review the provided options:

• Methotrexate: While commonly used for rheumatoid arthritis, it may be used off-label for peripheral arthritis in AS, but it is not typically the primary agent of choice.
• Hydroxychloroquine: This DMARD is mainly effective for rheumatoid arthritis and systemic lupus erythematosus. It has limited efficacy for the peripheral arthritis seen in AS.
• Sulfasalazine: This is a recognized treatment option for peripheral arthritis associated with ankylosing spondylitis and is often considered.
• Leflunomide: This DMARD has demonstrated effectiveness in treating peripheral arthritis within the spectrum of spondyloarthropathies, including ankylosing spondylitis. It targets inflammatory pathways relevant to these conditions.

Conclusion on Agent of Choice

Considering the options for treating the peripheral manifestations of ankylosing spondylitis, Leflunomide is considered an appropriate and effective disease-modifying agent.